Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Eli Lilly has decided to wait for the readout of the second of its two phase 3 trials for tirzepatide in obesity, rather than filing on the strength of its first, positive study.

Eli Lilly, after tirzepatide's late-stage cardio win, plots regulatory filings this year As for Alzheimer’s and other neurocognitive disorders, the research showed that use of the new diabetes ...

Having made waves the world over, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly’s tirzepatide are set to enter the Indian ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

The endorsement comes in response to new clinical trial data from a competitor's weight loss drug, which Leerink believes reinforces the market potential for Eli Lilly's tirzepatide. The recent Phase ...

At the heart of Eli Lilly's recent success and future prospects are its GLP-1 receptor agonists, Mounjaro (tirzepatide) for diabetes and Zepbound (tirzepatide) for obesity. These drugs have shown ...

NVO currently markets its obesity drug Wegovy and diabetes drug Ozempic, both of which contain the active ingredient semaglutide — a direct competitor to Lilly’s tirzepatide. Shares of Viking ...

Eli Lilly plans to submit an approval review to the FDA based on the Phase 3 results for heart failure, expecting to launch it within this year. CEO Ricks said, "Tirzepatide has confirmed efficacy ...

On Wednesday, Wells Fargo (NYSE:WFC) reiterated its Overweight rating and $1,000.00 price target on Eli Lilly (NYSE ... consensus expectations for 2025 tirzepatide sales, a low-teens quarter ...